Cut the uncertainty of eClinical service providers to unlock decentralized clinical trials

eClinical technologies promise easier access to patients and all the benefits of decentralized clinical trials (DCTs). But uncertainty is delaying adoption and a lack of familiarity with e-Technologies is a big barrier to their use.

Trial sponsors need to know “What good looks like” for newer technologies or service providers before they can be adopted for a clinical study.

Many people have direct experience of “what good looks like” for established services. If not, they can ask colleagues for appropriate questions or criteria to develop a suitable qualification Request for Information (RFI) template that will elicit relevant and important details to determine the best options.

In contrast, very few people have direct experience of the technologies that enable DCTs. E-Technologies have only been used in a tiny fraction of studies, and because they are new advances the technologies themselves, as well as how the ways they are deployed, are continuing to evolve.

Sponsors’ assessments of the quality of new technology providers often do not adequately identify all potential risks. The Diligent Qualification Platform uses a comprehensive set of qualification standards specifically compiled to assess newer technologies, and gives sponsors access to details of each vendor against those standards.

Find out more about:

• The range of technologies covered by the Diligent Qualification Platform
• The processes and competencies assessed for technology providers
• and the steps taken to chase and review provider information to ensure it is complete and valid.

Simply complete the form on this page for instant access